Q3 Earnings Estimate for Scienture Issued By Maxim Group

Scienture Holdings, Inc. (NASDAQ:SCNX) – Maxim Group issued their Q3 2026 earnings estimates for shares of Scienture in a report released on Tuesday, September 29th. Maxim Group analyst N. Rahman expects that the company will post earnings of ($1.50) per share for the quarter. The consensus estimate for Scienture’s current full-year earnings is ($0.23) per share. Maxim Group also issued estimates for Scienture’s Q4 2026 earnings at ($0.75) EPS, FY2026 earnings at ($5.75) EPS and FY2027 earnings at $0.00 EPS.

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Scienture in a research note on Monday, September 21st. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $37.50.

Scienture Stock Down 6.5%

Shares of NASDAQ SCNX opened at $3.71 on Monday. The company has a market cap of $152.33 million, a price-to-earnings ratio of -1.77 and a beta of 3.34. The company has a current ratio of 3.04, a quick ratio of 2.97 and a debt-to-equity ratio of 0.15. Scienture has a 12 month low of $3.35 and a 12 month high of $65.00. The stock has a 50-day moving average price of $8.98 and a two-hundred day moving average price of $9.35.

Scienture (NASDAQ:SCNX) last issued its quarterly earnings data on Thursday, August 13th. The company reported ($1.75) earnings per share for the quarter, topping the consensus estimate of ($2.25) by $0.50. The business had revenue of $0.34 million during the quarter, compared to analyst estimates of $1.96 million.

Institutional Investors Weigh In On Scienture

A hedge fund recently bought a new position in Scienture stock. Susquehanna International Group LLP bought a new position in Scienture Holdings, Inc. (NASDAQ:SCNX) in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor bought 235,117 shares of the company’s stock, valued at approximately $82,000. Susquehanna International Group LLP owned approximately 0.57% of Scienture at the end of the most recent reporting period. 5.68% of the stock is owned by institutional investors.

Scienture Company Profile

Scienture Holdings, Inc is a specialty pharmaceutical company focused on developing and commercializing therapies for central nervous system and other underserved medical conditions. The company’s strategy centers on differentiated medicines designed to address unmet patient and caregiver needs, including alternative formulations and delivery options.

Scienture’s lead product is ONYDA XR (clonidine hydrochloride) extended-release oral suspension, a non-stimulant prescription treatment for attention-deficit/hyperactivity disorder (ADHD).